The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs

Trials

Benjamin Kasenda¹  Benjamin Speich¹  Hannah Ewald¹  Heiner C. Bucher¹  Lars G. Hemkens¹  Aviv Ladanie¹  Juan Martin-Liberal²  Francesco Sclafani³  Arnav Agarwal⁴  Tiago V. Pereira⁵  John P. A. Ioannidis⁶  Thomas Schmid⁷  Florian Naudet⁸ 

[1] Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital and University of Basel;Catalan Institute of Oncology (ICO) Hospitalet, Melanoma, Sarcoma and GU Tumors Unit;Department of Medicine, The Royal Marsden NHS Foundation Trust;Department of Medicine, University of Toronto;Health Technology Assessment Unit, Institute of Education and Health Sciences, Oswaldo Cruz German Hospital;Meta-Research Innovation Center at Stanford (METRICS), Stanford University;St. Clara Hospital;Univ Rennes, CHU Rennes, Inserm, CIC 1414 [(Centre d’Investigation Clinique de Rennes)];

关键词: US Food and Drug Administration (FDA);    Drug regulation;    Marketing authorization;    Approval package;    Drugs and biologics;    Clinical trials;   

DOI  :  10.1186/s13063-018-2877-z

来源: DOAJ

【 摘 要 】

Abstract Background The available evidence on the benefits and harms of novel drugs and therapeutic biologics at the time of approval is reported in publicly available documents provided by the US Food and Drug Administration (FDA). We aimed to create a comprehensive database providing the relevant information required to systematically analyze and assess this early evidence in meta-epidemiological research. Methods We designed a modular and flexible database of systematically collected data. We identified all novel cancer drugs and therapeutic biologics approved by the FDA between 2000 and 2016, recorded regulatory characteristics, acquired the corresponding FDA approval documents, identified all clinical trials reported therein, and extracted trial design characteristics and treatment effects. Herein, we describe the rationale and design of the data collection process, particularly the organization of the data capture, the identification and eligibility assessment of clinical trials, and the data extraction activities. Discussion We established a comprehensive database on the comparative effects of drugs and therapeutic biologics approved by the FDA over a time period of 17 years for the treatment of cancer (solid tumors and hematological malignancies). The database provides information on the clinical trial evidence available at the time of approval of novel cancer treatments. The modular nature and structure of the database and the data collection processes allow updates, expansions, and adaption for a continuous meta-epidemiological analysis of novel drugs. The database allows us to systematically evaluate benefits and harms of novel drugs and therapeutic biologics. It provides a useful basis for meta-epidemiological research on the comparative effects of innovative cancer treatments and continuous evaluations of regulatory developments.

【 授权许可】

Unknown